parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in rod photoreceptor cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 482	0.85
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 10332

CADM1 in astrocytes, braak-0.48 (p 0.188) → +0.42 (p 0.258)receipt 10340
CADM1 in dopamine neurons, braak+0.55 (p 0.121) → +0.45 (p 0.230)receipt 10341

receipt 10341: CADM1 in dopamine neurons, braak

power: full sample +0.33 (p 0.188, n 18), 95% CI -0.17 to +0.69. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.36 (p 0.140, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.21 (p 0.408, n 18). could be the mix.
skeptic: leave-one-out range +0.24 to +0.46, sign flips 0; without severely affected donors +0.33 (p 0.188, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CADM1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 10340: CADM1 in astrocytes, braak

power: full sample +0.17 (p 0.493, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.26 (p 0.306, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.21 (p 0.398, n 18). could be the mix.
skeptic: leave-one-out range +0.07 to +0.32, sign flips 0; without severely affected donors +0.17 (p 0.493, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CADM1 in astrocytes.

case closed: nothing better to follow up.

loading the receipts